APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer’s mice via cyclophilin A independently of amyloid-β

Jun 14, 2021·
Axel Montagne
,
Angeliki M. Nikolakopoulou
,
Mikko T. Huuskonen
,
Abhay P. Sagare
,
Erica J. Lawson
,
Divna Lazic
,
Sanket v. Rege
,
Alexandra Grond
,
Edward Zuniga
,
Samuel R. Barnes
,
Jacob Prince
,
Meghana Sagare
Ruu Hsu
Ruu Hsu
,
Mary J. Mary J. LaDu
,
Russell E. Jacobs
,
Berislav v. Zlokogic
· 0 min read
Abstract
Apolipoprotein E4 (APOE4), the main susceptibility gene for Alzheimer’s disease (AD), leads to vascular dysfunction, amyloid-β pathology, neurodegeneration and dementia. How these different pathologies contribute to advanced-stage AD remains unclear. Using aged APOE knock-in mice crossed with 5xFAD mice, we show that, compared to APOE3, APOE4 accelerates blood-brain barrier (BBB) breakdown, loss of cerebral blood flow, neuronal loss and behavioral deficits independently of amyloid-β. BBB breakdown was associated with activation of the cyclophilin A-matrix metalloproteinase-9 BBB-degrading pathway in pericytes. Suppression of this pathway improved BBB integrity and prevented further neuronal loss and behavioral deficits in APOE4;5FAD mice while having no effect on amyloid-β pathology. Thus, APOE4 accelerates advanced-stage BBB breakdown and neurodegeneration in Alzheimer’s mice via the cyclophilin A pathway in pericytes independently of amyloid-β, which has implication for the pathogenesis and treatment of vascular and neurodegenerative disorder in AD.
Type
Publication
Nature Aging